drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00884 | DB14491 | 1,008 | 428 | [
"DDInter1604",
"DDInter725"
] | Risedronic acid | Ferrous fumarate | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1008,
24,
428
]
],
[
[
1008,
24,
1193
],
[
1193,
23,
428
]
],
[
[
1008,
40,
1485
],
[
1485,
24,
428
]
],
[
[
1008,
24,
1384
],
[
1384,... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc glucon... | Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a... |
DB08871 | DB10795 | 36 | 221 | [
"DDInter666",
"DDInter1486"
] | Eribulin | Poliovirus type 1 antigen (formaldehyde inactivated) | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
36,
24,
221
]
],
[
[
36,
64,
581
],
[
581,
24,
221
]
],
[
[
36,
24,
350
],
[
350,
24,
221
]
],
[
[
36,
63,
599
],
[
599,
24,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infl... | Eribulin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Eribulin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00238 | DB11581 | 188 | 1,456 | [
"DDInter1285",
"DDInter1926"
] | Nevirapine | Venetoclax | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
188,
25,
1456
]
],
[
[
188,
24,
1135
],
[
1135,
23,
1456
]
],
[
[
188,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
188,
24,
466
],
[
466,
... | [
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Nevirapine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a mo... |
DB00673 | DB08816 | 723 | 578 | [
"DDInter112",
"DDInter1802"
] | Aprepitant | Ticagrelor | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
723,
24,
578
]
],
[
[
723,
6,
8374
],
[
8374,
45,
578
]
],
[
[
723,
54,
19146
],
[
19146,
15,
578
]
],
[
[
723,
21,
28646
],
[
28646,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ticagrelor (Compound)
Aprepitant (Compound) causes Unspecified disorde... |
DB00421 | DB05812 | 443 | 1,374 | [
"DDInter1707",
"DDInter8"
] | Spironolactone | Abiraterone | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
443,
24,
1374
]
],
[
[
443,
1,
1561
],
[
1561,
1,
1374
]
],
[
[
443,
6,
3486
],
[
3486,
45,
1374
]
],
[
[
443,
21,
28809
],
[
28809,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} (Compo... | Spironolactone (Compound) resembles Testosterone (Compound) and Testosterone (Compound) resembles Abiraterone (Compound)
Spironolactone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Abiraterone (Compound)
Spironolactone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Ab... |
DB00679 | DB00792 | 684 | 832 | [
"DDInter1796",
"DDInter1878"
] | Thioridazine | Tripelennamine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
684,
24,
832
]
],
[
[
684,
24,
100
],
[
100,
63,
832
]
],
[
[
684,
25,
1264
],
[
1264,
63,
832
]
],
[
[
684,
24,
649
],
[
649,
1... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Thioridazine may lead to a major life threatening interaction when taken with Doxepin and Doxepi... |
DB00402 | DB09065 | 1,407 | 760 | [
"DDInter685",
"DDInter424"
] | Eszopiclone | Cobicistat | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1407,
25,
760
]
],
[
[
1407,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1407,
24,
723
],
[
723,
24,
760
]
],
[
[
1407,
25,
609
],
[
609,
... | [
[
[
"Eszopiclone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepi... |
DB00445 | DB12161 | 322 | 730 | [
"DDInter655",
"DDInter512"
] | Epirubicin | Deutetrabenazine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
322,
24,
730
]
],
[
[
322,
23,
112
],
[
112,
23,
730
]
],
[
[
322,
24,
1559
],
[
1559,
24,
730
]
],
[
[
322,
63,
521
],
[
521,
2... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine an... |
DB12500 | DB15822 | 283 | 69 | [
"DDInter714",
"DDInter1504"
] | Fedratinib | Pralsetinib | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
283,
24,
69
]
],
[
[
283,
63,
1213
],
[
1213,
24,
69
]
],
[
[
283,
64,
1017
],
[
1017,
24,
69
]
],
[
[
283,
62,
351
],
[
351,
24... | [
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Fedratinib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a... |
DB00903 | DB01278 | 1,680 | 1,021 | [
"DDInter686",
"DDInter1506"
] | Etacrynic acid | Pramlintide | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1680,
24,
1021
]
],
[
[
1680,
24,
708
],
[
708,
63,
1021
]
],
[
[
1680,
63,
891
],
[
891,
24,
1021
]
],
[
[
1680,
24,
688
],
[
688,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Predni... |
DB01105 | DB06822 | 222 | 802 | [
"DDInter1665",
"DDInter1812"
] | Sibutramine | Tinzaparin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
222,
24,
802
]
],
[
[
222,
64,
758
],
[
758,
24,
802
]
],
[
[
222,
25,
1427
],
[
1427,
63,
802
]
],
[
[
222,
63,
443
],
[
443,
2... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluoxetine"
],
[
"Fluoxeti... | Sibutramine may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Sibutramine may lead to a major life threatening interaction when taken with Vortioxetine and Vortioxetine may cause a moderat... |
DB00804 | DB01102 | 1,507 | 1,188 | [
"DDInter543",
"DDInter114"
] | Dicyclomine | Arbutamine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Arbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately . | Moderate | 1 | [
[
[
1507,
24,
1188
]
],
[
[
1507,
63,
1523
],
[
1523,
40,
1188
]
],
[
[
1507,
63,
19
],
[
19,
24,
1188
]
],
[
[
1507,
24,
1511
],
[
1511,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arbutamine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Arbutamine (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that cou... |
DB00277 | DB01215 | 1,031 | 1,418 | [
"DDInter1791",
"DDInter677"
] | Theophylline | Estazolam | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Minor | 0 | [
[
[
1031,
23,
1418
]
],
[
[
1031,
23,
523
],
[
523,
1,
1418
]
],
[
[
1031,
23,
1216
],
[
1216,
40,
1418
]
],
[
[
1031,
62,
905
],
[
905,
... | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Estazolam"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alprazolam"
],
[
... | Theophylline may cause a minor interaction that can limit clinical effects when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Theophylline may cause a minor interaction that can limit clinical effects when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Compound)
Th... |
DB00188 | DB00857 | 168 | 1,387 | [
"DDInter222",
"DDInter1768"
] | Bortezomib | Terbinafine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Minor | 0 | [
[
[
168,
23,
1387
]
],
[
[
168,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
168,
7,
6808
],
[
6808,
46,
1387
]
],
[
[
168,
18,
5077
],
[
5077,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Bortezomib (Compound) upregulates LGMN (Gene) and LGMN (Gene) is upregulated by Terbinafine (Compound)
Bortezomib (Compound) downregulates MVP (Gene) and MVP (Gene) is upregulated by Terbinafine (Compound)
Bortezomib (Compoun... |
DB00204 | DB00738 | 228 | 485 | [
"DDInter580",
"DDInter1420"
] | Dofetilide | Pentamidine | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Major | 2 | [
[
[
228,
25,
485
]
],
[
[
228,
6,
8374
],
[
8374,
45,
485
]
],
[
[
228,
18,
4930
],
[
4930,
57,
485
]
],
[
[
228,
21,
28722
],
[
28722,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Pentam... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pentamidine (Compound)
Dofetilide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Pentamidine (Compound)
Dofetilide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Pentamidine (Compound)
Dofetilid... |
DB01023 | DB11130 | 409 | 407 | [
"DDInter716",
"DDInter1344"
] | Felodipine | Opium | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
409,
24,
407
]
],
[
[
409,
63,
104
],
[
104,
24,
407
]
],
[
[
409,
24,
849
],
[
849,
24,
407
]
],
[
[
409,
23,
578
],
[
578,
24,... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyram... |
DB06603 | DB12245 | 39 | 823 | [
"DDInter1387",
"DDInter1863"
] | Panobinostat | Triclabendazole | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
39,
25,
823
]
],
[
[
39,
62,
1247
],
[
1247,
23,
823
]
],
[
[
39,
25,
1612
],
[
1612,
24,
823
]
],
[
[
39,
64,
1010
],
[
1010,
2... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Panobinostat may lead to a major life threatening interaction when taken with Fostemsavir and Fos... |
DB00342 | DB11732 | 1,181 | 1,097 | [
"DDInter1770",
"DDInter1027"
] | Terfenadine | Lasmiditan | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1181,
24,
1097
]
],
[
[
1181,
24,
971
],
[
971,
63,
1097
]
],
[
[
1181,
24,
77
],
[
77,
24,
1097
]
],
[
[
1181,
25,
478
],
[
478,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and ... |
DB00284 | DB00364 | 1,647 | 417 | [
"DDInter11",
"DDInter1717"
] | Acarbose | Sucralfate | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a _cytoprotective agent_, protec... | Moderate | 1 | [
[
[
1647,
24,
417
]
],
[
[
1647,
21,
28845
],
[
28845,
60,
417
]
],
[
[
1647,
24,
820
],
[
820,
62,
417
]
],
[
[
1647,
63,
1152
],
[
1152,... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Acarbose",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} ... | Acarbose (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Sucralfate (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Acarbo... |
DB00673 | DB12010 | 723 | 214 | [
"DDInter112",
"DDInter785"
] | Aprepitant | Fostamatinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
723,
24,
214
]
],
[
[
723,
24,
976
],
[
976,
24,
214
]
],
[
[
723,
63,
1428
],
[
1428,
24,
214
]
],
[
[
723,
24,
861
],
[
861,
6... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Is... |
DB00059 | DB00814 | 1,560 | 1,171 | [
"DDInter1404",
"DDInter1143"
] | Pegaspargase | Meloxicam | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
1560,
24,
1171
]
],
[
[
1560,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
1560,
24,
936
],
[
936,
63,
1171
]
],
[
[
1560,
24,
912
],
[
912,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor and Cangrelor may cause a moderate interaction that could ... |
DB00060 | DB06663 | 912 | 1,154 | [
"DDInter947",
"DDInter1398"
] | Interferon beta-1a | Pasireotide | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
912,
24,
1154
]
],
[
[
912,
24,
1247
],
[
1247,
23,
1154
]
],
[
[
912,
24,
663
],
[
663,
24,
1154
]
],
[
[
912,
24,
1662
],
[
1662,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfametho... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken... |
DB00637 | DB01041 | 1,557 | 770 | [
"DDInter128",
"DDInter1789"
] | Astemizole | Thalidomide | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1557,
24,
770
]
],
[
[
1557,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1557,
7,
7669
],
[
7669,
46,
770
]
],
[
[
1557,
25,
609
],
[
609,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Astemizole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Astemizole (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Astemizole may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause ... |
DB01169 | DB11110 | 57 | 603 | [
"DDInter120",
"DDInter1115"
] | Arsenic trioxide | Magnesium citrate | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
57,
24,
603
]
],
[
[
57,
64,
789
],
[
789,
24,
603
]
],
[
[
57,
25,
9
],
[
9,
24,
603
]
],
[
[
57,
25,
484
],
[
484,
63,
6... | [
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Foscarnet"
],
[... | Arsenic trioxide may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Arsenic trioxide may lead to a major life threatening interaction when taken with Methotrimeprazine and Methotrimepr... |
DB00373 | DB09038 | 461 | 1,450 | [
"DDInter1809",
"DDInter636"
] | Timolol | Empagliflozin | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
461,
24,
1450
]
],
[
[
461,
25,
659
],
[
659,
63,
1450
]
],
[
[
461,
24,
1061
],
[
1061,
24,
1450
]
],
[
[
461,
63,
1179
],
[
1179,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
... | Timolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause... |
DB00290 | DB00631 | 329 | 372 | [
"DDInter219",
"DDInter405"
] | Bleomycin | Clofarabine | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
329,
24,
372
]
],
[
[
329,
64,
1064
],
[
1064,
25,
372
]
],
[
[
329,
24,
1488
],
[
1488,
40,
372
]
],
[
[
329,
5,
11555
],
[
11555,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine"... | Bleomycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) resembles Clo... |
DB00420 | DB00986 | 508 | 1,192 | [
"DDInter1532",
"DDInter834"
] | Promazine | Glycopyrronium | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
508,
24,
1192
]
],
[
[
508,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
508,
24,
262
],
[
262,
24,
1192
]
],
[
[
508,
6,
2720
],
[
2720,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Cli... |
DB09570 | DB14443 | 1,480 | 987 | [
"DDInter1002",
"DDInter1931"
] | Ixazomib | Vibrio cholerae CVD 103-HgR strain live antigen | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1480,
24,
987
]
],
[
[
1480,
63,
1468
],
[
1468,
24,
987
]
],
[
[
1480,
64,
581
],
[
581,
24,
987
]
],
[
[
1480,
24,
738
],
[
738,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ixazomib may lead to a major life threatening interaction when taken with Infli... |
DB01142 | DB09117 | 1,264 | 957 | [
"DDInter593",
"DDInter1391"
] | Doxepin | Paraldehyde | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
1264,
24,
957
]
],
[
[
1264,
63,
126
],
[
126,
23,
957
]
],
[
[
1264,
63,
1648
],
[
1648,
24,
957
]
],
[
[
1264,
25,
593
],
[
593,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Wa... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may ... |
DB00270 | DB12010 | 1,428 | 214 | [
"DDInter993",
"DDInter785"
] | Isradipine | Fostamatinib | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1428,
24,
214
]
],
[
[
1428,
24,
723
],
[
723,
24,
214
]
],
[
[
1428,
63,
600
],
[
600,
24,
214
]
],
[
[
1428,
23,
467
],
[
467,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flu... |
DB00247 | DB04868 | 1,131 | 478 | [
"DDInter1194",
"DDInter1293"
] | Methysergide | Nilotinib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1131,
24,
478
]
],
[
[
1131,
21,
29544
],
[
29544,
60,
478
]
],
[
[
1131,
24,
1040
],
[
1040,
63,
478
]
],
[
[
1131,
24,
522
],
[
522,... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Weight increased"
],
[
"Weight increased",
"{u} (Sid... | Methysergide (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Nilotinib (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when t... |
DB06772 | DB08881 | 310 | 868 | [
"DDInter259",
"DDInter1925"
] | Cabazitaxel | Vemurafenib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
310,
24,
868
]
],
[
[
310,
6,
8374
],
[
8374,
45,
868
]
],
[
[
310,
6,
2479
],
[
2479,
57,
868
]
],
[
[
310,
21,
28847
],
[
28847,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Cabazitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Cabazitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Cabazitaxel (Compound) binds TUBA4A (Gene) and TUBA4A (Gene) is downregulated by Vemurafenib (Compound)
Cabazitaxel (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compou... |
DB00620 | DB06688 | 175 | 1,430 | [
"DDInter1855",
"DDInter1677"
] | Triamcinolone | Sipuleucel-T | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
175,
24,
1430
]
],
[
[
175,
25,
676
],
[
676,
63,
1430
]
],
[
[
175,
24,
1531
],
[
1531,
24,
1430
]
],
[
[
175,
63,
589
],
[
589,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"... | Triamcinolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinu... |
DB00197 | DB08930 | 1,324 | 1,459 | [
"DDInter1881",
"DDInter582"
] | Troglitazone | Dolutegravir | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Minor | 0 | [
[
[
1324,
23,
1459
]
],
[
[
1324,
24,
1419
],
[
1419,
23,
1459
]
],
[
[
1324,
23,
1101
],
[
1101,
23,
1459
]
],
[
[
1324,
24,
1320
],
[
13... | [
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarote... |
DB00258 | DB01115 | 666 | 336 | [
"DDInter270",
"DDInter1291"
] | Calcium acetate | Nifedipine | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
666,
24,
336
]
],
[
[
666,
24,
1428
],
[
1428,
1,
336
]
],
[
[
666,
24,
1081
],
[
1081,
40,
336
]
],
[
[
666,
21,
28769
],
[
28769,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
]... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine... |
DB00146 | DB00794 | 160 | 759 | [
"DDInter265",
"DDInter1521"
] | Calcifediol | Primidone | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
160,
24,
759
]
],
[
[
160,
24,
697
],
[
697,
40,
759
]
],
[
[
160,
24,
362
],
[
362,
1,
759
]
],
[
[
160,
25,
1041
],
[
1041,
63... | [
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
... | Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compou... |
DB06605 | DB09039 | 1,409 | 1,670 | [
"DDInter108",
"DDInter629"
] | Apixaban | Eliglustat | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1409,
24,
1670
]
],
[
[
1409,
63,
121
],
[
121,
24,
1670
]
],
[
[
1409,
64,
792
],
[
792,
24,
1670
]
],
[
[
1409,
24,
943
],
[
943,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Apixaban may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may caus... |
DB01041 | DB01211 | 770 | 609 | [
"DDInter1789",
"DDInter393"
] | Thalidomide | Clarithromycin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
770,
24,
609
]
],
[
[
770,
63,
1570
],
[
1570,
24,
609
]
],
[
[
770,
6,
7524
],
[
7524,
45,
609
]
],
[
[
770,
18,
3106
],
[
3106,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Thalidomide (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clarithromycin (Compound)
Thal... |
DB00075 | DB06674 | 541 | 908 | [
"DDInter1250",
"DDInter837"
] | Muromonab | Golimumab | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
541,
25,
908
]
],
[
[
541,
23,
1193
],
[
1193,
62,
908
]
],
[
[
541,
23,
1461
],
[
1461,
23,
908
]
],
[
[
541,
24,
496
],
[
496,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glucon... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Muromonab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin ... |
DB01149 | DB08899 | 851 | 129 | [
"DDInter1274",
"DDInter649"
] | Nefazodone | Enzalutamide | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
851,
24,
129
]
],
[
[
851,
6,
8374
],
[
8374,
45,
129
]
],
[
[
851,
21,
28703
],
[
28703,
60,
129
]
],
[
[
851,
63,
608
],
[
608,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Nefazodone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lid... |
DB00420 | DB11186 | 508 | 1,609 | [
"DDInter1532",
"DDInter1427"
] | Promazine | Pentoxyverine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
508,
24,
1609
]
],
[
[
508,
1,
623
],
[
623,
24,
1609
]
],
[
[
508,
40,
649
],
[
649,
24,
1609
]
],
[
[
508,
24,
506
],
[
506,
2... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a modera... | Promazine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Promazine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyver... |
DB00333 | DB09074 | 576 | 1,362 | [
"DDInter1166",
"DDInter1327"
] | Methadone | Olaparib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
576,
24,
1362
]
],
[
[
576,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
576,
25,
79
],
[
79,
24,
1362
]
],
[
[
576,
62,
491
],
[
491,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Methadone may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a mo... |
DB01097 | DB01128 | 1,377 | 918 | [
"DDInter1033",
"DDInter204"
] | Leflunomide | Bicalutamide | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
1377,
25,
918
]
],
[
[
1377,
6,
6017
],
[
6017,
45,
918
]
],
[
[
1377,
21,
29666
],
[
29666,
60,
918
]
],
[
[
1377,
63,
112
],
[
112,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Leflunomide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Bic... | Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bicalutamide (Compound)
Leflunomide (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Bicalutamide (Compound)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole an... |
DB01101 | DB09104 | 60 | 286 | [
"DDInter285",
"DDInter1118"
] | Capecitabine | Magnesium hydroxide | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
60,
23,
286
]
],
[
[
60,
62,
839
],
[
839,
24,
286
]
],
[
[
60,
63,
362
],
[
362,
24,
286
]
],
[
[
60,
23,
1539
],
[
1539,
24,
... | [
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
... | Capecitabine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Phen... |
DB00472 | DB09241 | 758 | 1,629 | [
"DDInter758",
"DDInter1186"
] | Fluoxetine | Methylene blue | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
758,
25,
1629
]
],
[
[
758,
24,
1148
],
[
1148,
24,
1629
]
],
[
[
758,
64,
73
],
[
73,
25,
1629
]
],
[
[
758,
25,
593
],
[
593,
... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isop... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Fluoxetine may lead to a major life threatening interaction when taken with Phentermine and Phentermine ... |
DB01064 | DB01268 | 1,148 | 1,151 | [
"DDInter987",
"DDInter1731"
] | Isoprenaline | Sunitinib | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1148,
24,
1151
]
],
[
[
1148,
7,
10269
],
[
10269,
57,
1151
]
],
[
[
1148,
18,
2183
],
[
2183,
57,
1151
]
],
[
[
1148,
21,
28762
],
[
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Isoprenaline",
"{u} (Compound) upregulates {v} (Gene)",
"DHX29"
],
[
"DHX29",
"{u} (Gene) is downregulated by {... | Isoprenaline (Compound) upregulates DHX29 (Gene) and DHX29 (Gene) is downregulated by Sunitinib (Compound)
Isoprenaline (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Sunitinib (Compound)
Isoprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Sunitinib ... |
DB01067 | DB11921 | 959 | 1,019 | [
"DDInter826",
"DDInter492"
] | Glipizide | Deflazacort | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
959,
24,
1019
]
],
[
[
959,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
959,
24,
192
],
[
192,
24,
1019
]
],
[
[
959,
24,
1619
],
[
1619,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and E... |
DB00584 | DB13620 | 610 | 948 | [
"DDInter638",
"DDInter1499"
] | Enalapril | Potassium gluconate | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Major | 2 | [
[
[
610,
25,
948
]
],
[
[
610,
63,
176
],
[
176,
23,
948
]
],
[
[
610,
24,
1254
],
[
1254,
23,
948
]
],
[
[
610,
24,
848
],
[
848,
2... | [
[
[
"Enalapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
... | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium gluconate
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Insu... |
DB00317 | DB08865 | 883 | 1,593 | [
"DDInter810",
"DDInter448"
] | Gefitinib | Crizotinib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
883,
24,
1593
]
],
[
[
883,
5,
11582
],
[
11582,
44,
1593
]
],
[
[
883,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
883,
7,
18110
],
[
18110,... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) treats {v} (Disease)",
"lung cancer"
],
[
"lung cancer",
"{u} (Disease) is treated by... | Gefitinib (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Gefitinib (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Crizotinib (Compound)
Ge... |
DB00078 | DB01254 | 1,172 | 1,213 | [
"DDInter898",
"DDInter484"
] | Ibritumomab tiuxetan | Dasatinib | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1172,
25,
1213
]
],
[
[
1172,
23,
539
],
[
539,
62,
1213
]
],
[
[
1172,
24,
1136
],
[
1136,
63,
1213
]
],
[
[
1172,
24,
563
],
[
563,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Denosumab ... |
DB00227 | DB06317 | 1,463 | 1,626 | [
"DDInter1098",
"DDInter630"
] | Lovastatin | Elotuzumab | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
1463,
24,
1626
]
],
[
[
1463,
24,
973
],
[
973,
24,
1626
]
],
[
[
1463,
24,
310
],
[
310,
63,
1626
]
],
[
[
1463,
63,
367
],
[
367,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabaz... |
DB00841 | DB01276 | 532 | 123 | [
"DDInter577",
"DDInter706"
] | Dobutamine | Exenatide | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
532,
24,
123
]
],
[
[
532,
63,
1685
],
[
1685,
24,
123
]
],
[
[
532,
24,
222
],
[
222,
24,
123
]
],
[
[
532,
24,
1254
],
[
1254,
... | [
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
... | Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and ... |
DB01072 | DB06655 | 915 | 5 | [
"DDInter129",
"DDInter1077"
] | Atazanavir | Liraglutide | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
915,
24,
5
]
],
[
[
915,
63,
353
],
[
353,
23,
5
]
],
[
[
915,
24,
1142
],
[
1142,
24,
5
]
],
[
[
915,
63,
870
],
[
870,
24,
... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlis... |
DB00675 | DB06595 | 888 | 1,491 | [
"DDInter1744",
"DDInter1214"
] | Tamoxifen | Midostaurin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
888,
24,
1491
]
],
[
[
888,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
888,
23,
112
],
[
112,
23,
1491
]
],
[
[
888,
24,
1017
],
[
1017,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazol... |
DB00193 | DB00561 | 534 | 1,048 | [
"DDInter1841",
"DDInter591"
] | Tramadol | Doxapram | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Major | 2 | [
[
[
534,
25,
1048
]
],
[
[
534,
24,
543
],
[
543,
1,
1048
]
],
[
[
534,
24,
537
],
[
537,
40,
1048
]
],
[
[
534,
21,
28936
],
[
28936,
... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxapram"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) resembles Doxapram (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Doxapram (Compound)
Tramadol (... |
DB01438 | DB09054 | 585 | 384 | [
"DDInter1438",
"DDInter905"
] | Phenazopyridine | Idelalisib | Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during urination. In the USA, this drug was previously marked by Roche but has been discontinued by the FDA. It is still us... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
585,
24,
384
]
],
[
[
585,
63,
305
],
[
305,
24,
384
]
],
[
[
585,
24,
850
],
[
850,
24,
384
]
],
[
[
585,
24,
1613
],
[
1613,
6... | [
[
[
"Phenazopyridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Phenazopyridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Esch... | Phenazopyridine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Phenazopyridine may cause a moderate interaction that could exacerbat... |
DB00443 | DB00691 | 251 | 1,058 | [
"DDInter195",
"DDInter1237"
] | Betamethasone | Moexipril | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
251,
24,
1058
]
],
[
[
251,
24,
1638
],
[
1638,
1,
1058
]
],
[
[
251,
24,
954
],
[
954,
40,
1058
]
],
[
[
251,
23,
115
],
[
115,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Comp... |
DB00317 | DB01259 | 883 | 392 | [
"DDInter810",
"DDInter1024"
] | Gefitinib | Lapatinib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
883,
35,
392
]
],
[
[
883,
6,
2192
],
[
2192,
45,
392
]
],
[
[
883,
7,
17061
],
[
17061,
46,
392
]
],
[
[
883,
18,
20113
],
[
20113,
... | [
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"EGFR"
],
[
"EGFR",
"{u... | Gefitinib (Compound) resembles Lapatinib (Compound) and
Gefitinib (Compound) binds EGFR (Gene) and EGFR (Gene) is bound by Lapatinib (Compound)
Gefitinib (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) is upregulated by Lapatinib (Compound)
Gefitinib (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregula... |
DB08904 | DB11581 | 375 | 1,456 | [
"DDInter342",
"DDInter1926"
] | Certolizumab pegol | Venetoclax | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
375,
25,
1456
]
],
[
[
375,
64,
259
],
[
259,
24,
1456
]
],
[
[
375,
24,
1129
],
[
1129,
63,
1456
]
],
[
[
375,
25,
1476
],
[
1476,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacep... | Certolizumab pegol may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e s... |
DB01235 | DB06723 | 1,191 | 115 | [
"DDInter1054",
"DDInter58"
] | Levodopa | Aluminum hydroxide | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1191,
23,
115
]
],
[
[
1191,
21,
28775
],
[
28775,
60,
115
]
],
[
[
1191,
63,
401
],
[
401,
23,
115
]
],
[
[
1191,
24,
1468
],
[
1468,... | [
[
[
"Levodopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Levodopa",
"{u} (Compound) causes {v} (Side Effect)",
"Phlebitis"
],
[
"Phlebitis",
"{u} (Side Effect) is ca... | Levodopa (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Aluminum hydroxide (Compound)
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with A... |
DB00226 | DB01168 | 1,000 | 1,053 | [
"DDInter845",
"DDInter1526"
] | Guanadrel | Procarbazine | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1000,
24,
1053
]
],
[
[
1000,
63,
1648
],
[
1648,
24,
1053
]
],
[
[
1000,
24,
1376
],
[
1376,
24,
1053
]
],
[
[
1000,
24,
885
],
[
885... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and... |
DB00054 | DB00500 | 1,432 | 24 | [
"DDInter6",
"DDInter1831"
] | Abciximab | Tolmetin | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Moderate | 1 | [
[
[
1432,
24,
24
]
],
[
[
1432,
24,
886
],
[
886,
1,
24
]
],
[
[
1432,
24,
831
],
[
831,
40,
24
]
],
[
[
1432,
24,
121
],
[
121,
63,... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
"... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Tolmetin (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Tolmetin (Compound)
Abci... |
DB01253 | DB06589 | 628 | 1,250 | [
"DDInter664",
"DDInter1400"
] | Ergometrine | Pazopanib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
628,
24,
1250
]
],
[
[
628,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
628,
18,
2999
],
[
2999,
57,
1250
]
],
[
[
628,
21,
28658
],
[
28658,... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Ergometrine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ergometrine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Ergometrine (Compound) downregulates PTPRK (Gene) and PTPRK (Gene) is downregulated by Pazopanib (Compound)
Ergometrine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Ergome... |
DB00959 | DB09038 | 1,486 | 1,450 | [
"DDInter1191",
"DDInter636"
] | Methylprednisolone | Empagliflozin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1486,
24,
1450
]
],
[
[
1486,
63,
461
],
[
461,
24,
1450
]
],
[
[
1486,
23,
659
],
[
659,
63,
1450
]
],
[
[
1486,
24,
192
],
[
192,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol... |
DB00818 | DB11057 | 898 | 720 | [
"DDInter1538",
"DDInter1223"
] | Propofol | Mineral oil | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
898,
24,
720
]
],
[
[
898,
24,
927
],
[
927,
63,
720
]
],
[
[
898,
24,
1151
],
[
1151,
24,
720
]
],
[
[
898,
63,
79
],
[
79,
24,... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitini... |
DB01087 | DB09121 | 1,520 | 1,328 | [
"DDInter1520",
"DDInter140"
] | Primaquine | Aurothioglucose | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Major | 2 | [
[
[
1520,
25,
1328
]
],
[
[
1520,
64,
581
],
[
581,
24,
1328
]
],
[
[
1520,
25,
375
],
[
375,
24,
1328
]
],
[
[
1520,
63,
1555
],
[
1555,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"... | Primaquine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Primaquine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may ... |
DB00704 | DB14723 | 267 | 159 | [
"DDInter1263",
"DDInter1026"
] | Naltrexone | Larotrectinib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
267,
24,
159
]
],
[
[
267,
24,
1135
],
[
1135,
23,
159
]
],
[
[
267,
64,
78
],
[
78,
24,
159
]
],
[
[
267,
24,
1412
],
[
1412,
6... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Naltrexone may lead to a major life threatening interaction when taken with Droperidol and Droperidol may cause a... |
DB00331 | DB01045 | 1,645 | 463 | [
"DDInter1164",
"DDInter1590"
] | Metformin | Rifampicin | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
1645,
24,
463
]
],
[
[
1645,
24,
542
],
[
542,
24,
463
]
],
[
[
1645,
63,
305
],
[
305,
24,
463
]
],
[
[
1645,
24,
959
],
[
959,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Esch... |
DB00026 | DB01030 | 1,184 | 869 | [
"DDInter94",
"DDInter1835"
] | Anakinra | Topotecan | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1184,
24,
869
]
],
[
[
1184,
24,
613
],
[
613,
24,
869
]
],
[
[
1184,
24,
310
],
[
310,
63,
869
]
],
[
[
1184,
25,
1064
],
[
1064,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxe... |
DB00252 | DB11767 | 362 | 1,583 | [
"DDInter1460",
"DDInter1643"
] | Phenytoin | Sarilumab | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
362,
24,
1583
]
],
[
[
362,
24,
267
],
[
267,
24,
1583
]
],
[
[
362,
1,
759
],
[
759,
24,
1583
]
],
[
[
362,
25,
1409
],
[
1409,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Phenytoin (Compound) resembles Primidone (Compound) and Primidone may cause a moderate interaction that could exac... |
DB01124 | DB03754 | 1,411 | 1,400 | [
"DDInter1828",
"DDInter1883"
] | Tolbutamide | Tromethamine | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th e... | Minor | 0 | [
[
[
1411,
23,
1400
]
],
[
[
1411,
1,
959
],
[
959,
23,
1400
]
],
[
[
1411,
24,
1529
],
[
1529,
24,
1400
]
],
[
[
1411,
63,
1445
],
[
1445,... | [
[
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tromethamine"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a minor i... | Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Tromethamine
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that... |
DB00444 | DB12500 | 63 | 283 | [
"DDInter1765",
"DDInter714"
] | Teniposide | Fedratinib | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
63,
24,
283
]
],
[
[
63,
24,
351
],
[
351,
23,
283
]
],
[
[
63,
24,
1339
],
[
1339,
62,
283
]
],
[
[
63,
24,
327
],
[
327,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotr... |
DB00603 | DB01098 | 303 | 14 | [
"DDInter1137",
"DDInter1622"
] | Medroxyprogesterone acetate | Rosuvastatin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Minor | 0 | [
[
[
303,
23,
14
]
],
[
[
303,
6,
8374
],
[
8374,
45,
14
]
],
[
[
303,
7,
2900
],
[
2900,
57,
14
]
],
[
[
303,
18,
1870
],
[
1870,
57... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (... | Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rosuvastatin (Compound)
Medroxyprogesterone acetate (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Rosuvastatin (Compound)
Medroxyprogesterone acetate (Compound) downregulates MYC (Gene) and MYC (Gene) i... |
DB00682 | DB01124 | 126 | 1,411 | [
"DDInter1951",
"DDInter1828"
] | Warfarin | Tolbutamide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
126,
24,
1411
]
],
[
[
126,
24,
959
],
[
959,
40,
1411
]
],
[
[
126,
63,
245
],
[
245,
40,
1411
]
],
[
[
126,
6,
10215
],
[
10215,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Wa... |
DB00086 | DB10344 | 1,167 | 992 | [
"DDInter1712",
"DDInter818"
] | Streptokinase | Ginger | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1167,
24,
992
]
],
[
[
1167,
64,
1578
],
[
1578,
24,
992
]
],
[
[
1167,
25,
1421
],
[
1421,
63,
992
]
],
[
[
1167,
24,
1347
],
[
1347,... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin... | Streptokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Streptokinase may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate inte... |
DB00790 | DB01225 | 664 | 500 | [
"DDInter1431",
"DDInter645"
] | Perindopril | Enoxaparin | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
664,
24,
500
]
],
[
[
664,
21,
29173
],
[
29173,
60,
500
]
],
[
[
664,
40,
1638
],
[
1638,
24,
500
]
],
[
[
664,
63,
305
],
[
305,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Perindopril",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema peripheral"
],
[
"Oedema peripheral",
"{u} (Si... | Perindopril (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Enoxaparin (Compound)
Perindopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Perindopril may cause ... |
DB00087 | DB01030 | 599 | 869 | [
"DDInter41",
"DDInter1835"
] | Alemtuzumab | Topotecan | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
599,
24,
869
]
],
[
[
599,
24,
613
],
[
613,
24,
869
]
],
[
[
599,
24,
310
],
[
310,
63,
869
]
],
[
[
599,
63,
1184
],
[
1184,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Caba... |
DB00106 | DB01242 | 618 | 1,237 | [
"DDInter4",
"DDInter410"
] | Abarelix | Clomipramine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
618,
24,
1237
]
],
[
[
618,
25,
684
],
[
684,
1,
1237
]
],
[
[
618,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
618,
24,
401
],
[
401,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazi... | Abarelix may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Abareli... |
DB00983 | DB06655 | 480 | 5 | [
"DDInter776",
"DDInter1077"
] | Formoterol | Liraglutide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
480,
24,
5
]
],
[
[
480,
62,
870
],
[
870,
24,
5
]
],
[
[
480,
63,
245
],
[
245,
24,
5
]
],
[
[
480,
24,
1326
],
[
1326,
24,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
... | Formoterol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride ... |
DB04868 | DB10343 | 478 | 962 | [
"DDInter1293",
"DDInter160"
] | Nilotinib | Bacillus calmette-guerin substrain tice live antigen | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
478,
25,
962
]
],
[
[
478,
63,
617
],
[
617,
24,
962
]
],
[
[
478,
64,
1057
],
[
1057,
25,
962
]
],
[
[
478,
25,
1342
],
[
1342,
... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bu... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Nilotinib may lead to a major life threatening interaction when taken w... |
DB01579 | DB08882 | 341 | 1,281 | [
"DDInter1439",
"DDInter1070"
] | Phendimetrazine | Linagliptin | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
341,
24,
1281
]
],
[
[
341,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
341,
21,
28762
],
[
28762,
60,
1281
]
],
[
[
341,
64,
73
],
[
73,
... | [
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Phendimetrazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
... | Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Phendimetrazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Linagliptin (Compound)
Phendimetrazine may lead to a majo... |
DB01268 | DB04948 | 1,151 | 1,084 | [
"DDInter1731",
"DDInter1083"
] | Sunitinib | Lofexidine | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1151,
24,
1084
]
],
[
[
1151,
62,
112
],
[
112,
23,
1084
]
],
[
[
1151,
63,
618
],
[
618,
24,
1084
]
],
[
[
1151,
24,
774
],
[
774,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix... |
DB06043 | DB06674 | 1,644 | 908 | [
"DDInter1328",
"DDInter837"
] | Olaratumab | Golimumab | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1644,
25,
908
]
],
[
[
1644,
24,
200
],
[
200,
63,
908
]
],
[
[
1644,
24,
1136
],
[
1136,
24,
908
]
],
[
[
1644,
63,
66
],
[
66,
... | [
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candi... | Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab ... |
DB00046 | DB00275 | 1,179 | 217 | [
"DDInter940",
"DDInter1330"
] | Insulin lispro | Olmesartan | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Moderate | 1 | [
[
[
1179,
24,
217
]
],
[
[
1179,
24,
911
],
[
911,
40,
217
]
],
[
[
1179,
24,
1486
],
[
1486,
63,
217
]
],
[
[
1179,
23,
1621
],
[
1621,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomi... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) resembles Olmesartan (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone... |
DB00011 | DB06772 | 1,451 | 310 | [
"DDInter944",
"DDInter259"
] | Interferon alfa-n1 | Cabazitaxel | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
1451,
24,
310
]
],
[
[
1451,
24,
973
],
[
973,
24,
310
]
],
[
[
1451,
25,
139
],
[
139,
24,
310
]
],
[
[
1451,
24,
350
],
[
350,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Zidovudine and Zido... |
DB00468 | DB00983 | 1,424 | 480 | [
"DDInter1557",
"DDInter776"
] | Quinine | Formoterol | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1424,
24,
480
]
],
[
[
1424,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1424,
6,
6017
],
[
6017,
45,
480
]
],
[
[
1424,
7,
5998
],
[
5998,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Quinine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Formoterol (Compound)
Quinine (Compound) u... |
DB00331 | DB00877 | 1,645 | 629 | [
"DDInter1164",
"DDInter1678"
] | Metformin | Sirolimus | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1645,
24,
629
]
],
[
[
1645,
6,
14103
],
[
14103,
45,
629
]
],
[
[
1645,
7,
3218
],
[
3218,
46,
629
]
],
[
[
1645,
18,
5527
],
[
5527,... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Metformin",
"{u} (Compound) binds {v} (Gene)",
"SLC47A1"
],
[
"SLC47A1",
"{u} (Gene) is bound by {v} (Compound)",
... | Metformin (Compound) binds SLC47A1 (Gene) and SLC47A1 (Gene) is bound by Sirolimus (Compound)
Metformin (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) is upregulated by Sirolimus (Compound)
Metformin (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Sirolimus (Compound)
Metformin (Compound)... |
DB01235 | DB01377 | 1,191 | 1,283 | [
"DDInter1054",
"DDInter1119"
] | Levodopa | Magnesium oxide | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1191,
23,
1283
]
],
[
[
1191,
24,
1468
],
[
1468,
62,
1283
]
],
[
[
1191,
63,
104
],
[
104,
23,
1283
]
],
[
[
1191,
24,
820
],
[
820,
... | [
[
[
"Levodopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdil... |
DB00358 | DB11642 | 1,010 | 938 | [
"DDInter1140",
"DDInter1480"
] | Mefloquine | Pitolisant | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1010,
24,
938
]
],
[
[
1010,
23,
112
],
[
112,
23,
938
]
],
[
[
1010,
24,
28
],
[
28,
24,
938
]
],
[
[
1010,
63,
600
],
[
600,
2... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisac... |
DB01064 | DB01159 | 1,148 | 419 | [
"DDInter987",
"DDInter854"
] | Isoprenaline | Halothane | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
1148,
24,
419
]
],
[
[
1148,
24,
774
],
[
774,
63,
419
]
],
[
[
1148,
24,
1264
],
[
1264,
24,
419
]
],
[
[
1148,
63,
688
],
[
688,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Halothane
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin ... |
DB09034 | DB12332 | 1,313 | 1,619 | [
"DDInter1733",
"DDInter1626"
] | Suvorexant | Rucaparib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1313,
24,
1619
]
],
[
[
1313,
63,
222
],
[
222,
23,
1619
]
],
[
[
1313,
23,
1135
],
[
1135,
23,
1619
]
],
[
[
1313,
64,
1419
],
[
1419... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Suvorexant may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol ... |
DB00912 | DB01211 | 473 | 609 | [
"DDInter1581",
"DDInter393"
] | Repaglinide | Clarithromycin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
473,
24,
609
]
],
[
[
473,
6,
8374
],
[
8374,
45,
609
]
],
[
[
473,
21,
28898
],
[
28898,
60,
609
]
],
[
[
473,
63,
600
],
[
600,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Repaglinide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Clarithromycin (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fl... |
DB00918 | DB12010 | 1,373 | 214 | [
"DDInter49",
"DDInter785"
] | Almotriptan | Fostamatinib | Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1373,
24,
214
]
],
[
[
1373,
63,
723
],
[
723,
24,
214
]
],
[
[
1373,
24,
1213
],
[
1213,
24,
214
]
],
[
[
1373,
25,
222
],
[
222,
... | [
[
[
"Almotriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Almotriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Almotriptan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Almotriptan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Das... |
DB08873 | DB09079 | 74 | 1,496 | [
"DDInter221",
"DDInter1296"
] | Boceprevir | Nintedanib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
74,
24,
1496
]
],
[
[
74,
63,
609
],
[
609,
24,
1496
]
],
[
[
74,
64,
477
],
[
477,
24,
1496
]
],
[
[
74,
25,
840
],
[
840,
24,
... | [
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Boceprevir may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol ma... |
DB00396 | DB00414 | 989 | 590 | [
"DDInter1529",
"DDInter16"
] | Progesterone | Acetohexamide | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
989,
24,
590
]
],
[
[
989,
24,
1017
],
[
1017,
63,
590
]
],
[
[
989,
1,
155
],
[
155,
63,
590
]
],
[
[
989,
63,
176
],
[
176,
24... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Progesterone (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate inter... |
DB00023 | DB00619 | 305 | 1,419 | [
"DDInter127",
"DDInter909"
] | Asparaginase Escherichia coli | Imatinib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
305,
24,
1419
]
],
[
[
305,
25,
1101
],
[
1101,
23,
1419
]
],
[
[
305,
24,
1627
],
[
1627,
62,
1419
]
],
[
[
305,
24,
1686
],
[
1686,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexaro... | Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ca... |
DB01244 | DB11691 | 762 | 1,499 | [
"DDInter192",
"DDInter1258"
] | Bepridil | Naldemedine | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
762,
24,
1499
]
],
[
[
762,
63,
723
],
[
723,
24,
1499
]
],
[
[
762,
25,
1670
],
[
1670,
24,
1499
]
],
[
[
762,
24,
1478
],
[
1478,
... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Bepridil may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a m... |
DB00570 | DB01041 | 147 | 770 | [
"DDInter1936",
"DDInter1789"
] | Vinblastine | Thalidomide | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
147,
25,
770
]
],
[
[
147,
5,
11555
],
[
11555,
44,
770
]
],
[
[
147,
7,
3271
],
[
3271,
45,
770
]
],
[
[
147,
7,
19775
],
[
19775,
... | [
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Vinblastine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treate... | Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Thalidomide (Compound)
Vinblastine (Compound) upregulates NFKB1 (Gene) and NFKB1 (Gene) is bound by Thalidomide (Compound)
Vinblastine (Compound) upregulates RAI14 (Gene) and RAI14 (Gene) is downregulated by Thalid... |
DB00241 | DB01041 | 288 | 770 | [
"DDInter257",
"DDInter1789"
] | Butalbital | Thalidomide | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
288,
24,
770
]
],
[
[
288,
24,
849
],
[
849,
63,
770
]
],
[
[
288,
24,
1614
],
[
1614,
24,
770
]
],
[
[
288,
62,
168
],
[
168,
2... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilon... |
DB01110 | DB01222 | 86 | 617 | [
"DDInter1209",
"DDInter246"
] | Miconazole | Budesonide | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
86,
24,
617
]
],
[
[
86,
63,
1351
],
[
1351,
1,
617
]
],
[
[
86,
24,
423
],
[
423,
1,
617
]
],
[
[
86,
6,
8374
],
[
8374,
45,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flunisolide"
],
[
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide and Ciclesonide (Compound) resembles Budesonide (Compou... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.